Завод ДИОД logo
Завод ДИОД DIOD

Завод ДИОД Financial Statements 2007-2025 | DIOD

Key Metrics Завод ДИОД

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Operating Cash Flow Per Share

0.034 0.001 0.001 0.001 1.85 0.001 0.001 -0.001 - - - - - - - - 15.4 K

Free Cash Flow Per Share

-0.349 0.001 -0.117 -0.01 1.83 -0.171 0.001 -0.001 1.13 0.572 -0.363 -0.018 -0.071 -0.191 -0.241 -3.75 K 15.1 K

Cash Per Share

0.373 2.29 1.93 1.31 0.333 1.12 0.921 0.991 1.57 0.02 0.154 0.189 0.189 0.415 0.42 3.13 K 2.53 K

Price To Sales Ratio

2.63 1.25 1.21 1.32 0.661 0.486 0.564 0.337 0.399 0.241 0.317 0.548 0.974 1.94 1.88 0.0 0.0

Dividend Yield

0.05 0.0 0.074 0.057 0.089 0.089 0.0 0.0 0.028 0.079 0.031 0.036 0.036 0.003 0.008 45.3 -

Payout Ratio

8.63 0.002 0.596 1.04 0.601 3.03 -0.001 -0.0 -0.09 0.425 -0.071 1.67 0.422 0.063 0.065 0.044 -

Revenue Per Share

6 6.13 6.58 5.27 7.15 8.46 9.12 9.68 10.5 14 12.4 12.6 16.9 16.9 17 189 K 177 K

Net Income Per Share

0.092 0.442 0.992 0.38 0.7 0.12 -0.289 -1.54 -1.31 0.625 -1.71 0.148 1.4 1.78 4.08 33.1 K 25 K

Book Value Per Share

12.3 13.1 13.4 12.3 13.1 12.9 14.9 15.4 16.9 18.2 17.6 19.7 25.2 23.8 21.9 156 K 120 K

Tangible Book Value Per Share

10.2 11 11.3 10.3 11.9 11.5 10.7 11.3 11.2 9.03 9.63 11.7 9.62 8.17 6.95 74.4 K 96.3 K

Shareholders Equity Per Share

12.4 13.2 13.5 12.3 13.2 12.9 14.9 15.5 17 18.4 17.7 19.9 20.2 19.9 18.7 150 K 119 K

Interest Debt Per Share

- 0.0 0.514 0.019 0.126 0.781 0.872 0.598 1.47 5.99 10.1 11.3 9.11 7.75 7.05 61.2 K 20.1 K

Market Cap

1.44 B 703 M 727 M 684 M 435 M 376 M 465 M 298 M 384 M 309 M 361 M 630 M 1.51 B 3 B 2.93 B 293 K 293 K

Enterprise Value

1.41 B 595 M 686 M 635 M 439 M 417 M 513 M 305 M 263 M 761 M 1.17 B 1.55 B 2.24 B 3.58 B 3.42 B 488 M 159 M

P/E Ratio

171 17.4 8.02 18.4 6.76 34.2 -17.8 -2.12 -3.2 5.41 -2.3 46.6 11.8 18.5 7.83 0.001 0.001

P/OCF Ratio

469 7 K 7.01 K 7.66 K 2.55 7.13 K 5.9 K -3.65 K - - - - - - - - 0.002

P/FCF Ratio

-45.1 7.2 K -67.9 -720 2.58 -24.1 9.57 K -3.57 K 3.71 5.91 -10.8 -388 -233 -171 -133 -0.009 0.002

P/B Ratio

1.27 0.583 0.588 0.566 0.359 0.318 0.345 0.211 0.247 0.184 0.222 0.347 0.816 1.65 1.71 0.0 0.0

EV/Sales

2.56 1.06 1.14 1.23 0.668 0.539 0.622 0.344 0.273 0.593 1.03 1.35 1.44 2.31 2.19 0.282 0.098

EV/EBITDA

62.8 9.12 5.22 8.22 4.02 4.62 14.4 -4.61 20.8 4.11 186 10.3 8.9 13.8 6 1.08 0.445

EV/OCF

457 5.92 K 6.61 K 7.11 K 2.58 7.91 K 6.5 K -3.74 K - - - - - - - - 1.13

Earnings Yield

0.006 0.057 0.125 0.054 0.148 0.029 -0.056 -0.472 -0.312 0.185 -0.435 0.021 0.085 0.054 0.128 1.03 K 782

Free Cash Flow Yield

-0.022 0.0 -0.015 -0.001 0.387 -0.042 0.0 -0.0 0.27 0.169 -0.092 -0.003 -0.004 -0.006 -0.008 -117 473

Debt To Equity

- - 0.038 0.001 0.007 0.061 0.041 0.012 0.015 0.27 0.507 0.516 0.402 0.337 0.31 0.377 0.167

Debt To Assets

- - 0.033 0.001 0.006 0.05 0.034 0.01 0.011 0.179 0.299 0.3 0.205 0.183 0.171 0.22 0.115

Net Debt To EBITDA

-1.52 -1.65 -0.316 -0.629 0.037 0.455 1.34 -0.103 -9.59 2.44 129 6.09 2.89 2.23 0.862 1.08 0.444

Current Ratio

6.72 7.56 9.22 8.75 5.75 5.02 4.95 5.72 3.11 1.82 2.44 3.76 2.94 2.9 1.73 2.44 2.26

Interest Coverage

- 1.22 K 5.63 K 127 28.2 - -1.98 1.33 0.819 1.95 1.83 1.67 3.25 3.23 4.52 10.4 165

Income Quality

0.365 2.37 1.17 2.4 2.65 K 4.8 -4.13 0.58 - - - - - - - - 0.614

Sales General And Administrative To Revenue

0.295 0.053 0.039 0.038 0.042 0.176 0.045 0.057 0.029 0.019 0.144 0.024 0.101 0.097 0.103 0.089 -

Intangibles To Total Assets

0.145 0.139 0.135 0.137 0.08 0.085 0.232 0.224 0.257 0.332 0.264 0.237 0.395 0.425 0.441 0.317 0.139

Capex To Operating Cash Flow

11.4 0.028 104 11.6 0.012 297 0.384 -0.024 - - - - - - - - 0.016

Capex To Revenue

0.064 0.0 0.018 0.002 0.003 0.02 0.0 0.0 0.001 0.0 0.001 0.001 0.004 0.011 0.014 0.02 0.001

Capex To Depreciation

1.7 0.166 681 50.8 127 524 1.23 0.069 - - - - - - - - 0.113

Stock Based Compensation To Revenue

- - - - - - - - - - - - - - - - -

Graham Number

5.06 11.4 17.4 10.3 14.4 5.9 9.85 23.1 22.4 16.1 26.1 8.14 25.2 28.2 41.4 334 K 259 K

Return On Invested Capital, ROIC

0.001 0.025 0.063 0.035 0.062 0.01 -0.02 0.034 0.062 0.059 0.082 0.018 0.065 0.077 0.164 0.162 0.172

Return On Tangible Assets, ROTA

0.007 0.033 0.074 0.031 0.048 0.008 -0.021 -0.108 -0.079 0.034 -0.077 0.006 0.058 0.084 0.216 0.189 0.169

Graham Net Net

2.26 1.88 4.71 4.1 3.5 3.73 2.83 3.49 2.26 -2.29 -3.2 -4.14 -4.82 -2.69 -3.45 -23.9 K 14 K

Working Capital

744 M 809 M 835 M 815 M 755 M 735 M 736 M 834 M 790 M 602 M 978 M 1.32 B 1.09 B 934 M 523 M 661 M 506 M

Tangible Asset Value

931 M 1 B 1.04 B 1.01 B 1.09 B 1.06 B 971 M 1.03 B 1.02 B 826 M 882 M 1.07 B 880 M 748 M 636 M 681 M 881 M

Net Current Asset Value, NCAV

654 M 716 M 743 M 726 M 674 M 668 M 638 M 733 M 670 M 472 M 516 M 481 M 345 M 243 M 145 M 199 M 433 M

Invested Capital

1.19 B 1.27 B 1.3 B 1.28 B 1.15 B 1.1 B 1.38 B 1.48 B 1.6 B 1.73 B 2.01 B 2.38 B 3.01 B 2.81 B 2.34 B 1.81 B 1.11 B

Average Receivables

154 M 176 M 354 M 394 M 399 M 312 M 263 M 275 M 324 M 517 M 730 M 785 M 798 M 691 M 539 M 531 M -

Average Payables

14.5 M 22.6 M 53.6 M 95.9 M 99.9 M 97.7 M 81.8 M 78.4 M 109 M 86.9 M 30.7 M 48.1 M 66 M 40.5 M 46.5 M 34.6 M -

Average Inventory

342 M 363 M 385 M 409 M 422 M 478 M 569 M 651 M 722 M 710 M 661 M 599 M 557 M 604 M 609 M 457 M -

Days Sales Outstanding

204 - 213 251 240 173 114 110 107 104 214 251 183 193 132 108 123

Days Payables Outstanding

21.5 21.1 46.5 145 141 93.2 99 39.1 121 70.7 55.6 0.343 49.2 17.5 22.5 26.1 11.4

Days Of Inventory On Hand

467 541 545 768 505 477 467 460 800 471 611 518 280 276 322 313 181

Receivables Turnover

1.79 - 1.71 1.45 1.52 2.11 3.19 3.31 3.42 3.5 1.71 1.45 1.99 1.89 2.77 3.37 2.96

Payables Turnover

17 17.3 7.85 2.52 2.58 3.92 3.69 9.34 3.01 5.16 6.56 1.06 K 7.42 20.8 16.2 14 32.1

Inventory Turnover

0.782 0.675 0.67 0.475 0.722 0.765 0.781 0.794 0.456 0.775 0.597 0.705 1.3 1.32 1.14 1.17 2.02

Return On Equity, ROE

0.007 0.033 0.073 0.031 0.053 0.009 -0.019 -0.1 -0.077 0.034 -0.097 0.007 0.069 0.089 0.219 0.221 0.21

Capex Per Share

0.383 0.0 0.118 0.011 0.022 0.171 0.0 0.0 0.007 0.003 0.01 0.018 0.071 0.191 0.241 3.75 K 253

All numbers in RUB currency

Quarterly Key Metrics Завод ДИОД

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q4 2008-Q2

Operating Cash Flow Per Share

0.017 0.0 0.72 0.405 0.762 0.627 0.342 0.491 1.39 0.56 - 0.001 -0.0 -0.0 -0.0 - - - - - - - - - - - - - -

Free Cash Flow Per Share

-0.175 0.0 0.711 0.344 0.704 0.616 0.342 0.541 1.31 0.528 -0.087 0.001 -0.0 -0.0 -0.0 0.566 0.566 0.286 0.286 -0.182 -0.182 -0.035 -0.035 -0.096 -0.096 -0.121 -0.121 -936 -1.87 K

Cash Per Share

2.52 2.3 2.66 1.93 2.12 1.37 0.699 0.334 1.4 1.11 1.04 0.921 1.03 0.991 1.38 1.57 0.046 0.02 0.161 0.154 0.228 0.189 0.302 0.415 0.418 0.42 0.367 - 2.83 K

Price To Sales Ratio

4.24 2.7 K 2.47 2.48 3 2.19 2.35 1.35 1.35 0.987 1.18 1.26 0.795 0.723 0.733 0.7 0.93 0.482 0.603 0.565 1.51 1.95 2.66 3.88 3.64 3.76 3.76 0.0 0.0

Dividend Yield

0.031 0.0 0.0 0.074 0.0 0.059 - 0.089 0.021 0.088 0.036 0.0 - 0.0 - 0.014 0.014 0.039 0.031 0.015 0.015 0.018 0.013 0.002 0.002 0.004 0.004 11.3 22.7

Payout Ratio

8.63 2.62 0.0 1.88 0.005 1.33 - 5.13 0.17 -3.56 0.819 -0.001 - -0.0 - -0.068 -0.133 0.425 0.425 0.538 -0.067 0.422 0.422 0.063 0.063 0.065 0.065 0.029 0.044

Revenue Per Share

3 0.003 3.3 3.21 3.37 3.19 2.44 3.52 3.71 4.16 4.3 4.09 4.97 4.51 5.17 6 4.54 7.01 7.01 6.97 2.73 8.47 8.47 8.46 8.46 8.52 8.52 88.7 K 94.5 K

Net Income Per Share

0.046 0.0 0.17 0.312 0.68 0.312 0.09 0.082 0.628 -0.101 0.225 -0.667 0.374 -0.374 -1.17 -0.865 -0.447 0.313 0.313 0.113 -0.913 0.698 0.698 0.888 0.888 2.04 2.04 12.5 K 16.5 K

Book Value Per Share

12.6 13.1 12.8 13.4 13.1 12.8 13.6 13.2 13.2 12.7 14.7 14.9 15.3 15.4 15.7 16.9 17.8 18.2 17.7 17.6 17.9 25.2 24.5 23.8 22.8 21.9 18.7 - 138 K

Tangible Book Value Per Share

10.5 11 10.7 11.3 11 10.8 12.4 11.9 11.7 11.4 10.8 10.7 11 11.3 11.8 11.2 8.69 9.03 9.11 9.63 9.87 9.62 8.9 8.17 7.56 6.95 7.2 - 85.4 K

Shareholders Equity Per Share

12.6 13.2 12.9 13.5 13.2 12.9 13.6 13.2 13.2 12.8 14.7 14.9 15.4 15.5 15.9 17 17.9 18.4 17.9 17.7 18 20.2 20.1 19.9 19.3 18.7 16.8 - 134 K

Interest Debt Per Share

- - 0.0 0.52 0.005 0.013 0.473 4.72 26.8 0.773 0.734 0.872 0.439 0.191 0.188 0.247 4.44 5.47 7.35 8.99 9.93 8.62 7.91 7.23 6.77 6.42 6.35 - 40.6 K

Market Cap

1.16 B 702 M 746 M 727 M 927 M 653 M 511 M 433 M 453 M 380 M 461 M 465 M 361 M 298 M 347 M 384 M 386 M 309 M 387 M 361 M 377 M 1.51 B 2.06 B 3 B 2.82 B 2.93 B 2.93 B 293 K 293 K

Enterprise Value

1.04 B 594 M 602 M 686 M 819 M 605 M 520 M 437 M 436 M 421 M 508 M 513 M 387 M 305 M 318 M 263 M 788 M 761 M 998 M 1.17 B 1.26 B 2.24 B 2.71 B 3.58 B 3.35 B 3.42 B 3.42 B - 323 M

P/E Ratio

69.1 6.56 K 12 6.38 3.72 5.6 15.9 14.3 1.99 -10.2 5.66 -1.93 2.64 -2.18 -0.813 -1.21 -2.36 2.7 3.38 8.69 -1.13 5.91 8.06 9.23 8.68 3.92 3.92 0.001 0.0

P/OCF Ratio

757 18.2 K 11.3 19.7 13.3 11.1 16.7 9.62 3.61 7.34 - 4.63 K -16.8 K -7.24 K -8.58 K - - - - - - - - - - - - - -

P/FCF Ratio

-72.8 19.1 K 11.5 23.1 14.4 11.3 16.7 8.75 3.81 7.79 -58.8 6.12 K -13.2 K -7.24 K -8.18 K 7.42 7.45 11.8 14.8 -21.7 -22.7 -466 -635 -343 -322 -265 -265 -0.034 -0.017

P/B Ratio

1.01 0.582 0.632 0.588 0.767 0.541 0.419 0.357 0.379 0.322 0.346 0.345 0.256 0.211 0.239 0.247 0.236 0.184 0.236 0.222 0.229 0.816 1.12 1.65 1.6 1.71 1.9 - 0.0

EV/Sales

3.79 2.29 K 2 2.34 2.65 2.02 2.39 1.36 1.3 1.09 1.31 1.38 0.852 0.739 0.671 0.479 1.9 1.19 1.55 1.83 5.07 2.88 3.5 4.62 4.33 4.39 4.38 - 0.374

EV/EBITDA

92.9 17.2 K 20.9 29.5 9.19 9.17 27.9 17.3 9.91 23.1 7.05 -21.1 6.46 22.8 5.4 -3.67 96.3 8.22 10.8 10.8 23.6 17.8 21.6 27.7 25.9 12 12 - 1.43

EV/OCF

676 15.4 K 9.14 18.5 11.7 10.3 17 9.71 3.48 8.13 - 5.11 K -18 K -7.4 K -7.85 K - - - - - - - - - - - - - -

Earnings Yield

0.004 0.0 0.021 0.039 0.067 0.045 0.016 0.017 0.126 -0.025 0.044 -0.13 0.095 -0.115 -0.308 -0.206 -0.106 0.092 0.074 0.029 -0.222 0.042 0.031 0.027 0.029 0.064 0.064 391 517

Free Cash Flow Yield

-0.014 0.0 0.087 0.043 0.07 0.088 0.06 0.114 0.263 0.128 -0.017 0.0 -0.0 -0.0 -0.0 0.135 0.134 0.085 0.068 -0.046 -0.044 -0.002 -0.002 -0.003 -0.003 -0.004 -0.004 -29.3 -58.5

Debt To Equity

- - 0.0 0.038 - 0.001 0.035 0.007 0.032 0.061 0.05 0.041 0.028 0.012 0.012 0.015 0.248 0.27 0.382 0.507 0.551 0.402 0.37 0.337 0.324 0.31 0.34 - 0.284

Debt To Assets

- - 0.0 0.033 - 0.001 0.029 0.006 0.026 0.05 0.041 0.034 0.023 0.01 0.008 0.011 0.17 0.179 0.238 0.299 0.323 0.205 0.195 0.183 0.177 0.171 0.192 - 0.178

Net Debt To EBITDA

-11 -3.13 K -4.98 -1.78 -1.21 -0.737 0.467 0.159 -0.375 2.25 0.662 -1.97 0.434 0.509 -0.497 1.69 49.1 4.88 6.59 7.49 16.6 5.79 5.19 4.46 4.13 1.72 1.72 - 1.43

Current Ratio

5 7.56 5.58 9.22 5.84 8.75 6.53 5.75 5.24 5.02 4.52 4.95 4.2 5.72 2.55 3.11 1.88 1.82 1.88 2.44 3.06 2.94 2.92 2.9 2.21 1.73 2.01 - 2.35

Interest Coverage

- - - 28.8 176 - - 0.055 0.012 - - -3 - - - - - 1.95 1.95 - - 3.25 3.25 3.23 3.23 4.52 4.52 165 10.4

Income Quality

0.365 1.44 4.23 1.3 1.12 2.01 3.8 5.96 2.21 -5.54 - -1.88 -0.631 1.21 0.379 - - - - - - - - - - - - - -

Sales General And Administrative To Revenue

0.295 0.272 0.0 - - 0.211 0.263 - - 0.168 0.184 -0.096 0.16 0.219 0.196 0.156 0.165 0.019 0.019 0.143 0.127 0.101 0.101 0.097 0.097 0.103 0.103 - 0.089

Intangibles To Total Assets

0.135 0.139 0.133 0.135 0.133 0.137 0.077 0.08 0.089 0.085 0.216 0.232 0.223 0.224 0.175 0.257 0.347 0.332 0.301 0.264 0.26 0.395 0.409 0.425 0.433 0.441 0.388 - 0.245

Capex To Operating Cash Flow

11.4 50.1 0.013 0.149 0.076 0.018 - 0.1 0.052 0.058 - 0.243 -0.27 - -0.048 - - - - - - - - - - - - - -

Capex To Revenue

0.064 7.44 0.003 0.019 0.017 0.003 - 0.014 0.02 0.008 0.02 0.0 0.0 - 0.0 0.001 0.001 0.0 0.0 0.001 0.002 0.004 0.004 0.011 0.011 0.014 0.014 0.011 0.02

Capex To Depreciation

1.7 302 0.082 0.803 0.587 0.099 - 2.35 0.404 0.365 - 2.62 0.381 - 0.183 - - - - - - - - - - - - - -

Stock Based Compensation To Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Graham Number

3.61 0.295 7.03 9.73 14.2 9.51 5.26 4.96 13.7 5.39 8.62 15 11.4 11.4 20.4 18.2 13.4 11.4 11.2 6.73 19.2 17.8 17.8 20 19.6 29.3 27.8 - 223 K

Return On Invested Capital, ROIC

0.0 0.0 0.009 0.009 0.045 0.019 0.004 0.005 0.024 -0.002 0.02 -0.038 0.014 -0.015 0.031 0.131 0.0 0.029 0.028 0.018 0.018 0.033 0.034 0.038 0.04 0.082 0.094 - 0.098

Return On Tangible Assets, ROTA

0.003 0.0 0.012 0.023 0.049 0.024 0.006 0.006 0.043 -0.007 0.016 -0.048 0.025 -0.026 -0.062 -0.052 -0.026 0.017 0.016 0.005 -0.04 0.029 0.031 0.042 0.044 0.108 0.112 - 0.102

Graham Net Net

1.26 4.87 4.24 4.71 4.42 4.56 3.3 3.51 3.48 3.69 2.68 2.83 3.18 3.49 2.35 2.26 -1.77 -5.29 -7.45 -8.66 -8.9 -4.82 -3.75 -2.69 -3.07 -3.45 -2.92 - -4.97 K

Working Capital

769 M 809 M 785 M 835 M 814 M 815 M 804 M 755 M 757 M 735 M 743 M 736 M 816 M 834 M 829 M 790 M 563 M 602 M 667 M 978 M 1.15 B 1.09 B 1.01 B 934 M 729 M 523 M 592 M - 583 M

Tangible Asset Value

959 M 1 B 983 M 1.04 B 1.01 B 1.01 B 1.11 B 1.09 B 1.06 B 1.06 B 973 M 971 M 1.01 B 1.03 B 1.08 B 1.02 B 795 M 826 M 834 M 882 M 903 M 880 M 814 M 748 M 692 M 636 M 658 M - 781 M

Net Current Asset Value, NCAV

677 M 716 M 692 M 743 M 726 M 726 M 723 M 674 M 682 M 668 M 645 M 638 M 717 M 733 M 725 M 670 M 437 M 472 M 424 M 516 M 533 M 345 M 294 M 243 M 194 M 145 M 172 M - 316 M

Invested Capital

1.22 B 1.27 B 1.24 B 1.3 B 1.28 B 1.28 B 1.19 B 1.15 B 1.14 B 1.1 B 1.36 B 1.38 B 1.47 B 1.48 B 1.47 B 1.6 B 1.68 B 1.73 B 1.75 B 2.01 B 2.2 B 3.01 B 2.91 B 2.81 B 2.57 B 2.34 B 2.07 B - 1.46 B

Average Receivables

182 M 331 M 325 M 356 M 375 M 363 M 384 M 355 M 322 M 318 M 264 M 311 M 315 M 398 M 405 M 291 M 150 M - - - - 787 M 808 M 754 M 627 M 551 M 526 M - -

Average Payables

33.8 M 15.9 M 24.6 M 22.5 M 44.8 M 70.1 M 90.2 M 72.2 M 56.2 M 55.3 M 69.1 M 92.2 M 62.4 M 190 M 217 M 117 M 121 M 98.5 M 72.6 M 75.9 M - 80.9 M 51.1 M 38.3 M 42.6 M 45.6 M 47.3 M - -

Average Inventory

349 M 365 M 369 M 379 M 397 M 408 M 414 M 441 M 448 M 470 M 518 M 542 M 584 M 636 M 677 M 719 M 748 M 678 M 637 M 680 M - 551 M 563 M 587 M 622 M 624 M 593 M - -

Days Sales Outstanding

- 126 K 89 108 105 117 139 121 74.6 85.7 62.6 62.8 71.8 58.3 101 46.2 65 - - - - 90.2 92.6 95.1 80.3 65.1 62.2 - 55.3

Days Payables Outstanding

37.9 10.7 K 12.3 20.4 10.9 59.9 74.2 90.6 13.5 44.1 15.2 52 30 20.5 115 41.3 84.9 34.9 26 23.5 97.9 24.3 16.7 8.65 9.68 11.1 11.5 - 9.25

Days Of Inventory On Hand

240 274 K 255 239 311 318 476 324 222 226 291 245 230 241 231 272 487 232 187 259 743 138 141 136 145 159 151 - 122

Receivables Turnover

- 0.001 1.01 0.834 0.855 0.767 0.648 0.745 1.21 1.05 1.44 1.43 1.25 1.54 0.895 1.95 1.38 - - - - 0.997 0.972 0.946 1.12 1.38 1.45 - 1.63

Payables Turnover

2.37 0.008 7.33 4.42 8.25 1.5 1.21 0.994 6.66 2.04 5.9 1.73 3 4.39 0.784 2.18 1.06 2.58 3.46 3.82 0.919 3.71 5.39 10.4 9.3 8.11 7.81 - 9.73

Inventory Turnover

0.376 0.0 0.353 0.377 0.29 0.283 0.189 0.278 0.406 0.398 0.309 0.367 0.392 0.373 0.39 0.33 0.185 0.388 0.481 0.348 0.121 0.652 0.638 0.66 0.622 0.568 0.596 - 0.737

Return On Equity, ROE

0.004 0.0 0.013 0.023 0.051 0.024 0.007 0.006 0.048 -0.008 0.015 -0.045 0.024 -0.024 -0.073 -0.051 -0.025 0.017 0.017 0.006 -0.051 0.035 0.035 0.045 0.046 0.109 0.121 - 0.123

Capex Per Share

0.191 0.021 0.009 0.06 0.058 0.011 - 0.049 0.072 0.033 0.087 0.0 0.0 - 0.0 0.003 0.003 0.001 0.001 0.005 0.005 0.035 0.035 0.096 0.096 0.121 0.121 936 1.87 K

All numbers in RUB currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Завод ДИОД DIOD
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Завод ДИОД plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 223.01 -0.99 % $ 395 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.68 1.85 % $ 777 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.38 3.21 % $ 261 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 212.3 5.5 % $ 5 B danmarkDanmark
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
BioVie BioVie
BIVI
$ 1.54 -2.53 % $ 2.28 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.33 -1.48 % $ 7.25 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.4 1.49 % $ 8.18 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 90.34 -1.28 % $ 96.9 B britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.76 0.19 % $ 1.25 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.53 -1.19 % $ 140 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.33 2.3 % $ 14.6 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Axon Enterprise Axon Enterprise
AXON
$ 586.28 3.15 % $ 44.4 B usaUSA
Biogen Biogen
BIIB
$ 173.03 -2.55 % $ 25.2 B usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.29 -5.01 % $ 631 M israelIsrael
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 12.91 0.78 % $ 531 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.9 0.17 % $ 27.2 B germanyGermany
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.55 8.86 % $ 747 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 15.32 5.73 % $ 1.01 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Cerus Corporation Cerus Corporation
CERS
$ 2.14 13.23 % $ 395 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.15 -0.44 % $ 1.47 B britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 3.81 -5.35 % $ 46.6 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 51.05 -0.32 % $ 103 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.5 0.46 % $ 118 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.36 -7.29 % $ 31.1 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 2.1 -4.34 % $ 5.32 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.42 6.77 % $ 134 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.22 -2.72 % $ 908 M israelIsrael
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 28.33 0.5 % $ 1.82 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA